Dihydrotestosterone and testosterone levels in men screened for prostate cancer: A study of a randomized population

被引:28
|
作者
Gustafsson, O
Norming, U
Gustafsson, S
Eneroth, P
Astrom, G
Nyman, CR
机构
[1] STOCKHOLM SODER HOSP,DEPT CLIN CHEM,S-11883 STOCKHOLM,SWEDEN
[2] NOVUM HUDDINGE HOSP,KAROLINSKA INST,CLIN RES CTR,UNIT APPL BIOCHEM,HUDDINGE,SWEDEN
来源
BRITISH JOURNAL OF UROLOGY | 1996年 / 77卷 / 03期
关键词
dihydrotestosterone; testosterone; sexual-hormones; prostate cancer; screening;
D O I
10.1046/j.1464-410X.1996.89120.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the possible relationship between serum levels of prostate specific antigen (PSA), dihydrotestosterone (DHT), testosterone, sexual-hormone binding globulin (SHBG) and tumour stage, grade and ploidy in 65 cases of prostate cancer diagnosed in a screening study compared to 130 controls from the same population. Patients, subjects and methods From a population of 26 602 men between the ages of 55 and 70 years, 2400 were selected randomly and invited to undergo screening for prostate cancer using a digital rectal examination, transrectal ultrasonography and PSA analysis. Among the 1782 attendees, 65 cases of prostate cancer were diagnosed. Each case was matched with two control subjects of similar age and prostate volume from the screening population. Frozen serum samples were analysed for PSA, DHT, testosterone and SHBG, and compared to the diagnosis and tumour stage, grade and ploidy. Comparisons between these variables, and multivariate and regression analyses were performed. Results There were significant differences in PSA level with all variables except tumour ploidy, DHT levels were slightly lower in patients with prostate cancer but the difference was not statistically significant. There was a trend towards lower DHT values in more advanced tumours and the difference for T-stages was close to statistical significance (P=0.059). Testosterone levels were lower in patients with cancer than in the control group, but the differences were not significant. There was no correlation between testosterone levels, tumour stage and ploidy, but the differences in testosterone level in tumours of a low grade of differentiation compared to those with intermediate and high grade was nearly significant (P=0.058). The testosterone/DHT ratio tended to be higher in patients with more advanced tumours, SHBG levels were lower in patients with cancer than in controls but the differences were not statistically significant. There were no systematic variations of tumour stage, grade and ploidy, Multivariate analysis showed that if the PSA level was known, then DHT, testosterone or SHBG added no further information concerning diagnosis, stage, grade or ploidy, Regression analysis on T-stage, PSA level and DHT showed an inverse linear relationship between PSA and DHT for stage T-3 (P=0.035), but there was no relationship between PSA and testosterone. Conclusion PSA was of value in discriminating between cases and controls and between various tumour stages and grades, but no statistically significant correlation was found for ploidy. If PSA level was known, no other variable added information in individual cases, Within a group, DHT levels tended to be lower among cases and in those with more advanced tumours, There was an inverse relationship between tumour volume, as defined by PSA level, and 5 alpha-reductase activity, as defined by DHT level, and the testosterone/DHT ratio. This trend was most obvious with T-stage, No systematic variation were found in the levels of testosterone or SHBG.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 50 条
  • [31] Dihydrotestosterone levels and survival in screening-detected prostate cancer:: A 15-yr follow-up study
    Kiellman, Anders
    Akre, Olof
    Norming, Ulf
    Toernblom, Magnus
    Gustafsson, Ove
    EUROPEAN UROLOGY, 2008, 53 (01) : 106 - 111
  • [32] Intermittent Androgen Suppression in Prostate Cancer: Testosterone Levels and Its Implication
    Mearini, Luigi
    Zucchi, Alessandro
    Costantini, Elisabetta
    Bini, Vittorio
    Porena, Massimo
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 (04) : 1218 - 1227
  • [33] Do evolutionary life-history trade-offs influence prostate cancer risk? a review of population variation in testosterone levels and prostate cancer disparities
    Alvarado, Louis Calistro
    EVOLUTIONARY APPLICATIONS, 2013, 6 (01): : 117 - 133
  • [34] Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review
    Shabsigh, R.
    Crawford, E. D.
    Nehra, A.
    Slawin, K. M.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2009, 21 (01) : 9 - 23
  • [35] Evidence for the integration of total and free testosterone levels in the management of prostate cancer
    Huynh, Linda My
    Huang, Erica
    Towe, Maxwell
    Liang, Karren
    el Khatib, Farouk M.
    Yafi, Faysal A.
    Ahlering, Thomas E.
    BJU INTERNATIONAL, 2022, 130 (01) : 76 - 83
  • [36] PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer
    Otto, S. J.
    Moss, S. M.
    Maattanen, L.
    Roobol, M.
    Zappa, M.
    Nelen, V.
    Kwiatkowski, M.
    Villers, A.
    Hugosson, J.
    Sanchez, A. Berenguer
    de Koning, H. J.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (17) : 3053 - 3060
  • [37] Current state of practice regarding testosterone supplementation therapy in men with prostate cancer
    Kovac, Jason R.
    Pan, Michael M.
    Lipshultz, Larry I.
    Lamb, Dolores J.
    STEROIDS, 2014, 89 : 27 - 32
  • [38] Lesions predictive for prostate cancer in a screened population:: First and second screening round findings
    Postma, R
    Roobol, M
    Schröder, FH
    van der Kwast, TH
    PROSTATE, 2004, 61 (03) : 260 - 266
  • [39] Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging
    Pierorazio, Phillip M.
    Ferrucci, Luigi
    Kettermann, Anna
    Longo, Dan L.
    Metter, E. Jeffrey
    Carter, H. Ballentine
    BJU INTERNATIONAL, 2010, 105 (06) : 824 - 829
  • [40] Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer
    Llukani, Elton
    Katz, Benjamin F.
    Agalliu, Ilir
    Lightfoot, Andrew
    Yu, Sue-Jean S.
    Kathrins, Martin
    Lee, Ziho
    Su, Yu-Kai
    Agnew, Kelly Monahan
    McGill, Alice
    Eun, Daniel D.
    Lee, David I.
    PROSTATE INTERNATIONAL, 2017, 5 (01) : 17 - 23